TomoTherapy Names Rafael Vaello Vice President of Global Sales : Former Philips Healthcare executive brings proven sales experience in oncology, imaging industries

TomoTherapy Incorporated (NASDAQ: TOMO), producer of the Hi·Art® treatment system for advanced radiation therapy, today announced that Rafael (Ralph) Vaello will join the company as vice president of global sales, effective December 1, 2008. Mr. Vaello, who will report to TomoTherapy CEO Fred Robertson, M.D., has spent the previous seven years leading the sales and field marketing group for Philips Healthcare’s Oncology Imaging division.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
TomoTherapy offers a revolutionary, efficient and versatile tool in the arsenal against cancer. The success in this battle depends on innovative technology, like the Hi·Art system, that enables aggressive treatment options and individualized patient care

MADISON, Wis. (PRWEB) November 24, 2008

"Ralph is an experienced, results-oriented sales leader. He has demonstrated repeated success at developing world-class sales organizations that meet or exceed their performance goals," said Dr. Robertson. "We are confident that Ralph's deep industry experience and strong management style, combined with our technology's recognized edge in the treatment of cancer patients, will accelerate our market penetration."

Mr. Vaello brings more than 15 years of sales expertise in the oncology and imaging industries to TomoTherapy, where he will be responsible for enhancing sales performance and expanding the company's global market presence.

Prior to joining TomoTherapy, Mr. Vaello served as vice president, sales and field marketing, for Philips Healthcare's Oncology Imaging division, where he exceeded aggressive budget plans in orders, sales and margin attainment. Mr. Vaello was previously director, global sales manager, for Marconi Medical Systems' Oncology division. Prior to that, he held various imaging and oncology sales positions for Picker International.

"TomoTherapy offers a revolutionary, efficient and versatile tool in the arsenal against cancer. The success in this battle depends on innovative technology, like the Hi·Art system, that enables aggressive treatment options and individualized patient care," said Mr. Vaello. "I'm very excited to join the company at such a promising time in the field of cancer treatment."

Shawn Guse, who held the role of interim vice president of global sales since August 25, 2008, will take on other executive responsibilities within the organization, including continuing as the CEO of TomoTherapy's proton therapy development subsidiary, Compact Particle Acceleration Corporation.

"Shawn has stepped in and provided valuable leadership in a critical role during his transition," said Dr. Robertson. "We appreciate Shawn's versatile talents and excellent leadership skills."

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.


Contact